Q-omics provides the consensus-scored PMCH profile across patient tissues and cancer cell-line models. PMCH expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PMCH is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PMCH RNA expression shows 10,519 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRP, KIRC, and PAAD as cancer lineages where PMCH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMCH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMCH survival associations across molecular data types. PMCH RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMCH RNA expression–survival associations across cancer types. High PMCH expression shows unfavorable associations in KIRP and ACC, but favorable associations in COAD, SKCM, BRCA and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PMCH RNA expression.
This table summarizes PMCH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PMCH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMCH shows higher tumor expression in KIRC, HNSC, UCEC, LUAD, KIRP and COAD. The KIRC box plot shows higher PMCH RNA expression in tumor versus normal tissue (log2 FC = +0.914, t-test p < 0.001).
This table shows molecular features associated with PMCH in patient tissues and cancer cell lines. In patient samples, PMCH shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PMCH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
